RGBP (Regen BioPharma) Total Liabilities: $5.62 Mil (As of Mar. 2026)


What is Regen BioPharma Total Liabilities?

Regen BioPharma RGBP +33.33% Total Liabilities is $5.62 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

Regen BioPharma's Total Liabilities for the quarter that ended in Mar. 2026 was $5.62 Mil.

Regen BioPharma's quarterly Total Liabilities increased from Sep. 2025 ($6.56 Mil) to Dec. 2025 ($6.81 Mil) but then declined from Dec. 2025 ($6.81 Mil) to Mar. 2026 ($5.62 Mil).

Regen BioPharma's annual Total Liabilities declined from Sep. 2023 ($5.46 Mil) to Sep. 2024 ($5.38 Mil) but then increased from Sep. 2024 ($5.38 Mil) to Sep. 2025 ($6.56 Mil).

Regen BioPharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Total Liabilities Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.70 8.60 5.46 5.38 6.56

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.87 6.01 6.56 6.81 5.62

Regen BioPharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Regen BioPharma's Total Liabilities for the fiscal year that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.556+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.56

Total Liabilities=Total Assets (A: Sep. 2025 )-Total Equity (A: Sep. 2025 )
=0.275--6.281
=6.56

Regen BioPharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.619+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.62

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=0.26--5.359
=5.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.62 Mil mean?
Regen BioPharma (RGBP) has a Total Liabilities of $5.62 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Regen BioPharma and its competitors.
Is Regen BioPharma's Total Liabilities too high?
Regen BioPharma's current Total Liabilities is $5.62 Mil.
How does Regen BioPharma's Total Liabilities compare to ENDV and ADTX?
Regen BioPharma's Total Liabilities of $5.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Regen BioPharma and its competitors. Regen BioPharma's current Total Liabilities is $5.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Total Liabilities is $5.62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Total Liabilities is $5.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.